ライフサイエンスコーパス: nab-paclitaxel

1 ion of the antimicrotubular drug Paclitaxel (nab-paclitaxel).

2 bine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel).

3 is pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel).

4 X) and Abraxane (nanoparticle albumin-bound (nab)-paclitaxel).

5 ckpoint (SAC) genes that enhance survival in nab-paclitaxel.

6 of FOLFIRINOX compared with gemcitabine plus nab-paclitaxel.

7 itional cohort treated with gemcitabine plus nab-paclitaxel.

8 nous gemcitabine and 125 mg/m(2) intravenous nab-paclitaxel.

9 did not enhance the efficacy of gemcitabine/nab-paclitaxel.

10 xel/bevacizumab, or atezolizumab/carboplatin/nab-paclitaxel.

11 reatment with FOLFIRINOX or gemcitabine plus nab-paclitaxel.

12 i-VEGFR included, or (G) mTOR inhibitor with nab-paclitaxel.

13 commonly being treated with gemcitabine and nab-paclitaxel.

14 L1 inhibitor atezolizumab plus paclitaxel or nab-paclitaxel.

15 Cav-1 overexpression enhanced sensitivity to nab-paclitaxel.

16 interaction that enables antibody coating of nab-paclitaxel.

17 d in the cancers noted above that respond to nab-paclitaxel.

18 al in patients treated with gemcitabine plus nab-paclitaxel.

19 d in the experimental arms, particularly for nab-paclitaxel.

20 rforms more efficaciously than docetaxel and nab-paclitaxel.

21 anisms of delivery and antitumor activity of nab-paclitaxel.

22 urvival with the addition of relacorilant to nab-paclitaxel (0.69 [95% CI 0.52-0.92]; 15.97 months [9

23 use of denosumab (7.4% (2.5% to 12.2%)) and nab-paclitaxel (1.7% (0.9% to 2.5%)), but not with GCSF

24 abine 800 mg/m(2), cisplatin 25 mg/m(2), and nab-paclitaxel 100 mg/m(2) intravenously once per day on

25 n day 1 and day 15 of every 28-day cycle and nab-paclitaxel 100 mg/m(2) of body surface area intraven

26 ard schedule of 3 weeks on and 1 week off of NAB-paclitaxel (100 mg/m(2) [arm B] or 125 mg/m(2) [arm

27 atin (area under the curve of 2, weekly) and nab-paclitaxel (100 mg/m(2) weekly) with vorinostat (400

28 intravenous atezolizumab (1200 mg) on day 1, nab-paclitaxel (100 mg/m(2)) on days 1, 8, and 15, and c

29 he curve 6 mg/mL per min every 3 weeks] plus nab-paclitaxel [100 mg/m(2) intravenously every week]) o

30 NAB-paclitaxel 125 mg/m(2) administered on days 1, 8, an

31 46 h) on days 1 and 15 of a 28-day cycle or nab-paclitaxel 125 mg/m(2) and gemcitabine 1000 mg/m(2),

32 PSN improved much faster under NAB-paclitaxel 125 mg/m(2) compared with NAB-paclitaxel

33 ease of the median time to resolve PSN after NAB-paclitaxel 125 mg/m(2) compared with NAB-paclitaxel

34 days 1 and 15; gemcitabine 1,000 mg/m(2) and nab-paclitaxel 125 mg/m(2) intravenously on days 1, 8 an

35 les of nivolumab 360 mg once every 3 weeks + nab-paclitaxel 125 mg/m(2) once on days 1 and 8, every 3

36 d with standard 28-day cycles of intravenous nab-paclitaxel 125 mg/m(2) plus gemcitabine 1000 mg/m(2)

37 uvant 4x sb-paclitaxel 175 mg/m(2) q2w or 8x nab-paclitaxel 125 mg/m(2) q1w, followed by 4x epirubici

38 res indicating better performance status) to nab-paclitaxel (125 mg per square meter of body-surface

39 Patients received either intravenous nab-paclitaxel (125 mg/m(2) on days 1, 8, and 15) for si

40 aily oral ibrutinib (560 mg) or placebo plus nab-paclitaxel (125 mg/m(2)) and gemcitabine).

41 djuvant (six cycles, arm B) gemcitabine) and nab-paclitaxel (125 mg/m(2)) on days 1, 8 and 15 of a 28

42 randomly assigned to receive gemcitabine and nab-paclitaxel (125 mg/m2) administered intravenously on

43 ously every 4 weeks for 6 cycles, and either nab-paclitaxel, 125 mg/m2 weekly for 12 weeks or days 1

44 y assigned in a 1:1 ratio to 12 times weekly NAB-paclitaxel 150 mg/m(2) (after study amendment, 125 m

45 acizumab with paclitaxel 90 mg/m(2) (arm A), nab-paclitaxel 150 mg/m(2) (arm B), or ixabepilone 16 mg

46 on of PFS (> 5 months) in patients receiving nab-paclitaxel 150 mg/m(2) weekly compared with docetaxe

47 nab-Paclitaxel 150 mg/m(2) weekly demonstrated significa

48 der NAB-paclitaxel 125 mg/m(2) compared with NAB-paclitaxel 150 mg/m(2).

49 ter NAB-paclitaxel 125 mg/m(2) compared with NAB-paclitaxel 150 mg/m(2).

50 ix patients per arm): a biweekly schedule of NAB-paclitaxel (150 mg/m(2) [arm A] or 125 mg/m(2) [arm

51 rilant (150 mg the day before, of, and after nab-paclitaxel); (2) nab-paclitaxel (80 mg/m(2)) + conti

52 ised in a 1:1 ratio to treatment with either nab-paclitaxel (200 g/m(2) on day 1), cisplatin (60 mg/m

53 ens were (m)FOLFIRINOX (38%) and gemcitabine-nab-paclitaxel (22%).

54 Patients received nab-paclitaxel 260 mg/m(2) administered intravenously fo

55 0 mg/m(2) for 14 days), taxane (Tax) -based (nab-paclitaxel 260 mg/m(2), docetaxel 75 or 100 mg/m(2))

56 -paclitaxel and NPC-1C than gemcitabine plus nab-paclitaxel (39% [15 of 38] vs 10% [4 of 40]; P = .00

57 to 19.7%)), GCSF (5.8% (5.4% to 6.1%)), and nab-paclitaxel (7.6% (7.1% to 8.1%)), but lower use of b

58 of, and after nab-paclitaxel infusion) plus nab-paclitaxel (80 mg/m(2) intravenously on days 1, 8, a

59 y before, of, and after nab-paclitaxel); (2) nab-paclitaxel (80 mg/m(2)) + continuous relacorilant (1

60 Patients were randomly assigned 1:1:1 to (1) nab-paclitaxel (80 mg/m(2)) + intermittent relacorilant

61 Guidelines recommend atezolizumab plus nab-paclitaxel (A + nP) for first-line treatment of unre

62 Nab-paclitaxel, a nanoparticle conjugate of paclitaxel t

63 Previously we described three nab-paclitaxel (Abraxane) nanoparticles coated with comm

64 -covalently bound to the albumin scaffold of nab-paclitaxel (ABX).

65 y contribute to the preclinical finding that nab-paclitaxel achieves a 33% higher tumor uptake relati

66 [95% CI 1.13-1.75; P = .002], respectively) nab-paclitaxel across all patients.

67 gemcitabine plus nanoparticle albumin-bound (NAB) -paclitaxel (adequate comorbidity profile) should b

68 NAB-paclitaxel administered at either 100 and 125 mg/m(2

69 ated dose (MTD) and single-agent activity of NAB-paclitaxel administered on a weekly basis to patient

70 e efficacy of docetaxel and gemcitabine plus nab-paclitaxel against B16F10 melanoma and SW1990 pancre

71 , respectively, whereas native docetaxel and nab-paclitaxel (albumin-paclitaxel nanoparticle, Abraxan

72 ice with human pancreatic cancer xenografts, nab-paclitaxel alone and in combination with gemcitabine

73 is the FDA/EMEA approved dose of gemcitabine-nab-paclitaxel along-with ATRA (45 mg/m(2) orally, days

74 ndomly assigned to receive atezolizumab plus nab-paclitaxel and 451 were assigned to receive placebo

75 f 1,206 patients started treatment, 606 with NAB-paclitaxel and 600 with sb-paclitaxel.

76 atment with atezolizumab in combination with nab-paclitaxel and anthracycline-based chemotherapy sign

77 ally, a possible mechanistic synergy between nab-paclitaxel and capecitabine has been cited as the ra

78 Addition of nivolumab to neoadjuvant nab-paclitaxel and carboplatin (studied in the first OPT

79 small molecule (doxorubicin), nanoparticles (nab-paclitaxel and doxorubicin liposomes), and a monoclo

80 the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine as first-line therapy for

81 nab-paclitaxel (n = 40) or gemcitabine plus nab-paclitaxel and NPC-1C (n = 38).

82 (95% CI, 0.4%-19.7%) in the gemcitabine plus nab-paclitaxel and NPC-1C group and 2.9% (95% CI, 0.4%-1

83 ly in patients treated with gemcitabine plus nab-paclitaxel and NPC-1C than gemcitabine plus nab-pacl

84 3-6.5 months; P = .22) with gemcitabine plus nab-paclitaxel and NPC-1C.

85 9-5.3 months; P = .80) with gemcitabine plus nab-paclitaxel and NPC-1C.

86 eived at least two doses of gemcitabine plus nab-paclitaxel and one dose of APX005M during cycle 1, a

87 s a predictive biomarker for the response to nab-paclitaxel and other albumin-based cancer therapeuti

88 rial of neoadjuvant chemo-immunotherapy with nab-paclitaxel and pembrolizumab.

89 tely 2 months compared with gemcitabine plus nab-paclitaxel and was also associated with fewer posttr

90 bel phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine a

91 regimens, including FOLFIRINOX, gemcitabine/nab-paclitaxel, and nanoliposomal irinotecan/fluorouraci

92 Thus, nab-paclitaxel appears to interact with tumors in a numb

93 ecan, and oxaliplatin as well as gemcitabine/nab-paclitaxel are active in the metastatic setting, the

94 oride, and oxaliplatin) and gemcitabine plus nab-paclitaxel are the 2 common first-line therapies for

95 plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) are the treatments of choice for patient

96 ted (143 in the sb-paclitaxel and 100 in the NAB-paclitaxel arm).

97 rapy with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel (Arm 2).

98 liplatin (mFOLFIRINOX, arm 1) or gemcitabine/nab-paclitaxel (arm 2).

99 ebrile neutropenia were less frequent in all nab-paclitaxel arms.

100 position the combination of relacorilant and nab-paclitaxel as a potential new standard treatment for

101 Additional studies of single-agent NAB-paclitaxel as well as platinum-based combinations ar

102 total of 20, 44, and three patients received nab-paclitaxel at 100, 125, and 150 mg/m(2), respectivel

103 Chemotherapy comprised of nab-paclitaxel at 125 mg/m(2) every week for 12 weeks fo

104 Nab-paclitaxel at a dosage of 125 mg/m2 weekly significa

105 itional options are atezolizumab/carboplatin/nab-paclitaxel, atezolizumab/carboplatin/paclitaxel/beva

106 nm fluorphore was chosen as a surrogate for nab-paclitaxel based on its similar molecular weight and

107 particles could allow reverse engineering of nab-paclitaxel binding antibodies, creating a modular pl

108 geting agent in combination with gemcitabine-nab-paclitaxel chemotherapy using a two-step adaptive co

109 a; CD40 agonistic antibody) with gemcitabine/nab-paclitaxel (chemotherapy) in patients with first-lin

110 nd D15) and either paclitaxel (cohort II) or nab-paclitaxel [cohort III (100 mg/m(2), D1, D8, and D15

111 role in immune activation exclusively in the nab-paclitaxel combination.

112 dings might suggest a potential advantage of nab-paclitaxel combined with trastuzumab and pertuzumab

113 and safety of weekly and every 3 week (q3w) nab-paclitaxel compared with docetaxel as first-line tre

114 rated superior efficacy and safety of weekly nab-paclitaxel compared with docetaxel, with a statistic

115 for patients receiving either dose of weekly nab-paclitaxel compared with docetaxel.

116 r paclitaxel and 0.35 muM and 0.0087 muM for nab-paclitaxel compared with mitotane concentrations of

117 We aimed to evaluate the efficacy of weekly nab-paclitaxel compared with the standard regimen of doc

118 Atezolizumab plus carboplatin and nab-paclitaxel could be a potential neoadjuvant regimen

119 or with CDK4/6 inhibitor, (C) anti PD-1 with nab-paclitaxel, (D) PARP inhibitor included, (E) and (F)

120 %) vs 39.0% (90% CI, 35%-43%) (P = .06) with nab-paclitaxel days 1 and 8 every 3 weeks.

121 g/m(2) (49%) and 100 mg/m(2) (45%) weekly of nab-paclitaxel demonstrated a higher overall response ra

122 significant investigator ORR for both weekly nab-paclitaxel doses versus docetaxel.

123 h first-line treatment with gemcitabine plus NAB-paclitaxel, ECOG PS 0 to 1, and favorable comorbidit

124 imilar across study groups when adjusted for nab-paclitaxel exposure; no new safety signals were obse

125 of atezolizumab versus placebo combined with nab-paclitaxel followed by doxorubicin plus cyclophospha

126 ates that sequential neoadjuvant gemcitabine/nab-paclitaxel followed by mFOLFIRINOX significantly imp

127 SOC chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel) followed by chemoradiation (standard gro

128 7% with mFOLFIRINOX and 48% with gemcitabine/nab-paclitaxel for all eligible patients starting treatm

129 enosumab for CSPC (26.4% v 33.1%; P < .001), nab-paclitaxel for breast or lung cancer (7.9% v 8.7%; P

130 patients at low risk for neutropenic fever, nab-paclitaxel for cancers with no evidence of superiori

131 uggest further investigation into the use of nab-paclitaxel for the treatment of ACC.

132 oped a platform technology that utilizes the nab-paclitaxel formulation of paclitaxel, Abraxane, in w

133 mplex nanoparticle albumin bound paclitaxel (nab-paclitaxel) formulation was chosen as a model drug.

134 Gemcitabine plus nanoparticle albumin-bound (NAB) paclitaxel (GA) significantly improved survival com

135 FOX) over the combination of gemcitabine and nab-paclitaxel (GEM-NABP) as first-line treatment of met

136 enia is a common side effect associated with nab-paclitaxel gemcitabine (Nab-Gem) therapy.

137 NALIRIFOX versus 9.2 months (8.3-10.6) with nab-paclitaxel-gemcitabine (hazard ratio 0.83; 95% CI 0.

138 edian overall survival was 8.5 months in the nab-paclitaxel-gemcitabine group as compared with 6.7 mo

139 The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemci

140 ade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitab

141 gression-free survival was 5.5 months in the nab-paclitaxel-gemcitabine group, as compared with 3.7 m

142 In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3

143 LIRIFOX group and eight (2%) patients in the nab-paclitaxel-gemcitabine group.

144 ents were randomly assigned (NALIRIFOX, 383; nab-paclitaxel-gemcitabine, 387; median follow-up 16.1 m

145 IFOX and 326 (86%) of 379 patients receiving nab-paclitaxel-gemcitabine; treatment-related deaths occ

146 H20 plus nab-paclitaxel/gemcitabine (PAG) or nab-paclitaxel/gemcitabine (AG).

147 taxel/gemcitabine compared with placebo plus nab-paclitaxel/gemcitabine (median 5.3 versus 6.0 months

148 b-paclitaxel/gemcitabine versus placebo plus nab-paclitaxel/gemcitabine (median of 9.7 versus 10.8 mo

149 omly assigned to treatment with PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) or nab-paclitaxel/gemci

150 PFS was shorter for ibrutinib plus nab-paclitaxel/gemcitabine compared with placebo plus na

151 Ibrutinib plus nab-paclitaxel/gemcitabine did not improve OS or PFS for

152 ty and efficacy of first-line ibrutinib plus nab-paclitaxel/gemcitabine treatment in patients with PD

153 cant difference in OS between ibrutinib plus nab-paclitaxel/gemcitabine versus placebo plus nab-pacli

154 reatic ductal adenocarcinoma (PDAC) includes nab-paclitaxel/gemcitabine.

155 Gemcitabine-nab-paclitaxel (GEMNAB) and fluorouracil, leucovorin, ir

156 nhibitor, atezolizumab, with carboplatin and nab-paclitaxel given as neoadjuvant treatment before sur

157 ither modified (m) FOLFIRINOX or Gemcitabine-nab-paclitaxel (GnP) as per physicians choice.

158 100 (30%) patients in the nab-paclitaxel group and 128 (38%) in the docetaxel plus

159 ncluded in the full analysis set (332 in the nab-paclitaxel group and 337 in the docetaxel plus carbo

160 9 of whom were randomly assigned (343 to the nab-paclitaxel group and 346 to the docetaxel plus carbo

161 were reported in three (1%) patients in the nab-paclitaxel group and five (2%) in the docetaxel plus

162 0 (66.3% [95% CI 61.2-71.4]) patients in the nab-paclitaxel group had a pathological complete respons

163 4 adverse events were nausea (22 [7%] in the nab-paclitaxel group vs 76 [23%] in the docetaxel plus c

164 (95% CI, 0.4%-18.7%) in the gemcitabine plus nab-paclitaxel group.

165 group vs 176 [32.8%] in the gemcitabine plus nab-paclitaxel group; P = .02), fewer comorbidities (med

166 ared with the control, native docetaxel, and nab-paclitaxel groups.

167 At 4 years, overall patients treated with NAB-paclitaxel had a significantly better iDFS compared

168 Patients receiving relacorilant plus nab-paclitaxel had a statistically significant improveme

169 screen in the PANC-1 cell line with the drug nab-paclitaxel has identified a group of spindle assembl

170 Intermittent relacorilant + nab-paclitaxel improved PFS (hazard ratio [HR], 0.66; lo

171 Intermittent relacorilant + nab-paclitaxel improved PFS, DOR, and OS compared with n

172 show whether the addition of relacorilant to nab-paclitaxel improves progression-free and overall sur

173 zumab plus chemotherapy with carboplatin and nab-paclitaxel in advanced NSCLC patients to explore pot

174 v-1 expression reduced uptake of albumin and nab-paclitaxel in cancer cells and rendered them resista

175 Selection for cellular resistance to nab-paclitaxel in cell culture correlated with a loss of

176 Further studies of nab-paclitaxel in combination with platinum are warrante

177 ed dose (MTD) of first-line gemcitabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma a

178 rall survival benefit with atezolizumab plus nab-paclitaxel in patients with PD-L1 immune cell-positi

179 factinib in combination with gemcitabine and nab-paclitaxel in patients with PDAC and may suggest fur

180 the efficacy and safety of atezolizumab plus nab-paclitaxel in patients with unresectable, locally ad

181 adjuvant chemotherapy with gemcitabine plus nab-paclitaxel in rPDAC (National Comprehensive Cancer N

182 We report efficacy and toxicity with nab-paclitaxel in this group.

183 ts of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in patients with recurrent platinum-sens

184 cusses the proposed mechanism of delivery of nab-paclitaxel, including an examination into a hypothes

185 cancer cells and rendered them resistant to nab-paclitaxel-induced apoptosis.

186 cycles (m)FOLFIRINOX or 2 cycles gemcitabine-nab-paclitaxel induction chemotherapy (+/-radiotherapy)

187 (150 mg orally the day before, of, and after nab-paclitaxel infusion) plus nab-paclitaxel (80 mg/m(2)

188 castration-sensitive prostate cancer (CSPC), nab-paclitaxel instead of paclitaxel for breast or lung

189 Patients were treated with NAB-paclitaxel intravenously during 30 minutes without c

190 Nab-paclitaxel is active in this group of patients with

191 le-negative breast cancer, atezolizumab plus nab-paclitaxel is an important therapeutic option in a d

192 s a stromal-targeting agent with gemcitabine-nab-paclitaxel is safe and tolerable.

193 ributing factor to the tumor accumulation of nab-paclitaxel is the binding of albumin to secreted pro

194 Nanoparticle albumin-bound paclitaxel (NAB-paclitaxel) is an albumin-bound formulation of pacli

195 Recent data also suggest that nab-paclitaxel may enhance tumor accumulation of gemcita

196 8 491 of 86 394 patients (21.4%) at risk for nab-paclitaxel (median $89), and 4170 of 13 386 patients

197 n days 1, 8, and 15 of each 28-day cycle) or nab-paclitaxel monotherapy (100 mg/m(2) intravenously on

198 ous relacorilant (100 mg once daily); or (3) nab-paclitaxel monotherapy (100 mg/m(2)).

199 central review compared with those receiving nab-paclitaxel monotherapy (hazard ratio 0.70 [95% CI 0.

200 d to the combination group (n=188) or to the nab-paclitaxel monotherapy group (n=193).

201 months) and DOR (HR, 0.36; P = .006) versus nab-paclitaxel monotherapy, while ORR was similar across

202 7 (P = .066) for the intermittent arm versus nab-paclitaxel monotherapy.

203 d not result in significant improvement over nab-paclitaxel monotherapy.

204 axel improved PFS, DOR, and OS compared with nab-paclitaxel monotherapy.

205 second-line treatment with gemcitabine plus nab-paclitaxel (n = 40) or gemcitabine plus nab-paclitax

206 and sixty-four patients received neoadjuvant nab-paclitaxel (n= 437) or sb-paclitaxel (n = 427); nab-

207 ezolizumab [n=1] and septic shock related to nab-paclitaxel [n=1]) and one (<1%) patient in the place

208 egression more effectively than Abraxane(R) (Nab-paclitaxel, N-PTX), free drug, and non-sensitive NPs

209 acy and safety of first-line toripalimab and nab-paclitaxel (nab-P) (n = 353; experimental arm) versu

210 Nanoparticulate albumin bound paclitaxel (nab-paclitaxel, nab-PTX) is among the most widely prescr

211 o micromolar affinity for HSA Peptide 40 and nab-paclitaxel nanoparticles.

212 0 mg/m(2) of gemcitabine plus 125 mg/m(2) of nab-paclitaxel once a week for 3 weeks, every 28 days.

213 to eryaspase plus chemotherapy (gemcitabine/nab-paclitaxel or fluorouracil [5-FU], leucovorin [LV],

214 cer who were treated with either gemcitabine/nab-paclitaxel or fluorouracil, leucovorin, irinotecan,

215 We compared nab-paclitaxel or ixabepilone once per week to paclitaxe

216 evaluate progression-free survival (PFS) for nab-paclitaxel or ixabepilone versus paclitaxel.

217 hange in PD-L1 expression occurred following nab-paclitaxel or pembrolizumab run-in, thus the primary

218 ast cancer received two weeks of neoadjuvant nab-paclitaxel or pembrolizumab, with baseline and post-

219 nds pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel) or chemotherapy.

220 igator's choice of chemotherapy (paclitaxel, nab-paclitaxel, or capecitabine).

221 bined platinum and a taxane (ie, paclitaxel, nab-paclitaxel, or docetaxel) (n = 9866), and combined p

222 rs chose capecitabine, a taxane (paclitaxel, nab-paclitaxel, or docetaxel), gemcitabine, or vinorelbi

223 ab (200 mg) every 3 weeks plus chemotherapy (nab-paclitaxel; paclitaxel; or gemcitabine plus carbopla

224 st-run-in tumor biopsy, followed by combined nab-paclitaxel/pembrolizumab.

225 with BRCA1 and/or BRCA2 tPVs was seen in the nab-paclitaxel plus carboplatin group (9 of 14 patients

226 4% and 92.9%, respectively) were seen in the nab-paclitaxel plus carboplatin group.

227 ndomized clinical trial on tPVs, deescalated nab-paclitaxel plus carboplatin was superior to nab-pacl

228 ere randomized to 12 weeks of treatment with nab-paclitaxel plus either carboplatin or gemcitabine; o

229 al of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcit

230 ibitors with anti-PD-1 immunotherapy or with nab-paclitaxel plus gemcitabine demonstrates promising a

231 (9 of 14 patients [64.3%]) compared with the nab-paclitaxel plus gemcitabine group (10 of 28 [35.7%])

232 The regimen of nab-paclitaxel plus gemcitabine has tolerable adverse ef

233 Combining LOAd703 with nab-paclitaxel plus gemcitabine in patients with advance

234 DAPT-TN, patients were randomized to receive nab-paclitaxel plus gemcitabine or carboplatin.

235 umor growth in mice given chemotherapeutics (nab-paclitaxel plus gemcitabine or liposomal irinotecan)

236 s with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved o

237 was increased by 2.8-fold in mice receiving nab-paclitaxel plus gemcitabine versus those receiving g

238 , arm 2 of LOKON001, which combines LOAd703, nab-paclitaxel plus gemcitabine, and atezolizumab, is on

239 -paclitaxel plus carboplatin was superior to nab-paclitaxel plus gemcitabine, particularly in patient

240 ghest-evaluated safe dose when combined with nab-paclitaxel plus gemcitabine.

241 cacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based pacl

242 phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical a

243 atients with metastatic breast cancer (MBC), nab-paclitaxel produced significantly higher antitumor a

244 The addition of relacorilant to nab-paclitaxel prolonged progression-free survival and i

245 In high-risk HR+/HER2- EBC, neoadjuvant nab-paclitaxel q1w appears superior to sb-paclitaxel q2w

246 nab-Paclitaxel q3w versus docetaxel was not different fo

247 pporting this relationship between SPARC and nab-paclitaxel remain largely correlative at this point.

248 tecan, and oxaliplatin) and gemcitabine plus nab-paclitaxel remain the mainstay of treatment for pati

249 treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel, respectively (P < .001).

250 The optimal neoadjuvant nab-paclitaxel schedule in terms of efficacy and safety

251 The pCR rates for nab-paclitaxel schedules in subgroups were only signific

252 -1 protein levels correlated positively with nab-paclitaxel sensitivity.

253 For second-line therapy, gemcitabine plus NAB-paclitaxel should be offered to patients with first-

254 Paclitaxel and nab-paclitaxel show in vitro inhibition of H295R and SW-

255 st cancer (EBC), nanoparticle albumin-bound (nab)-paclitaxel showed promising efficacy versus solvent

256 Continuous relacorilant + nab-paclitaxel showed numerically improved median PFS bu

257 ated that weekly nanoparticle albumin-bound (NAB)-paclitaxel significantly improves the pathologic co

258 Moreover, treatment with gemcitabine and nab-paclitaxel significantly reduces the overall number

259 nd 451 were assigned to receive placebo plus nab-paclitaxel (the intention-to-treat population).

260 bited resistance to the antitumor effects of nab-paclitaxel therapy.

261 with undergoing combination gemcitabine and nab-paclitaxel [time ratio (TR) = 1.26, 95% CI: 1.02-1.5

262 igher pathologic complete response rate with NAB-paclitaxel translated into a significantly improved

263 In vivo nab-paclitaxel treatment shows a greater decrease in tum

264 llax treatment, whereas native docetaxel and nab-paclitaxel treatments were ineffective.

265 The technology used to create nab-paclitaxel utilizes albumin to deliver paclitaxel, r

266 were predictive for the relative efficacy of nab-paclitaxel versus sb-paclitaxel.

267 5% CI, 1.9-4.1 months) with gemcitabine plus nab-paclitaxel vs 3.4 months (95% CI, 1.9-5.3 months; P

268 5% CI, 4.7-8.4 months) with gemcitabine plus nab-paclitaxel vs 5.0 months (95% CI, 3.3-6.5 months; P

269 Nab-paclitaxel was administered on days 1, 8, and 15 of

270 , 1.59; 95% CI, 1.31 to 1.93; P < .001), and nab-paclitaxel was not superior to paclitaxel (PFS, 9.3

271 nce per week was inferior to paclitaxel, and nab-paclitaxel was not superior with a trend toward infe

272 litaxel (n= 437) or sb-paclitaxel (n = 427); nab-paclitaxel was superior for pCR (20.8% versus 12.9%,

273 xic effects of grade 3 to 4 were higher with nab-paclitaxel weekly (33.7% vs 24.1%; P = .004).

274 Nab-paclitaxel weekly resulted in a significantly (signi

275 lues for GCSF were 26.6% v 32.1% (5.5%), for nab-paclitaxel were 7.3% v 15.1% (7.8%), and for branded

276 ian cumulative payments for gemcitabine with nab-paclitaxel were highest overall [median $74,051, int

277 FOLFIRINOX or gemcitabine along with nab-paclitaxel were used in 165 (85%) and 65 (34%) patie

278 n, blocks binding of all three antibodies to nab-paclitaxel when added in excess.

279 zed phase II trial comparing gemcitabine and nab-paclitaxel with and without immune checkpoint inhibi

280 APX005M (sotigalimab) with gemcitabine plus nab-paclitaxel, with and without nivolumab, in patients

281 ng peripheral neuropathy, was increased with nab-paclitaxel, with more frequent and earlier dose redu

282 APX005M and gemcitabine plus nab-paclitaxel, with or without nivolumab, is tolerable